BioAge Labs, Inc. develops clinical-stage biopharmaceutical candidates for cardiometabolic diseases by targeting the biology of human aging. Its news centers on BGE-102, a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases, including diabetic macular edema.
Recurring updates cover Phase 1 biomarker and tolerability data, indication development for inflammation-driven disease, and research into long-acting injectable and oral small-molecule APJ agonists for obesity. BioAge also reports financial results, public offerings, R&D presentations, and collaborations that use its human longevity data platform to identify metabolic-aging pathways.
BioAge Labs (NASDAQ: BIOA) will present at the 25th Annual Needham Virtual Healthcare Conference April 13–16, 2026. CEO Kristen Fortney will take part in a fireside chat on April 16 from 3:00–3:30 PM EDT.
One-on-one meetings will include CFO Dov Goldstein and CSO BJ Sullivan. A live webcast is available by registration and replays will be archived for 30 days in the investor section of the company's website.
BioAge (NASDAQ: BIOA) reported full-year 2025 results and Q4 updates on March 24, 2026. Key clinical highlights include positive interim Phase 1 data for oral NLRP3 inhibitor BGE-102 with an 86% median hsCRP reduction at 120 mg and planned Phase 2a initiation in 1H 2026. The company completed an upsized follow-on offering raising $132.3 million and held $285.1 million in cash and marketable securities as of December 31, 2025, estimating funding through 2029.
BioAge Labs (NASDAQ: BIOA) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026. CEO Kristen Fortney will join a fireside chat on February 26 from 10:40 AM to 11:05 AM ET; management will hold one-on-one meetings.
Live webcast registration is available and replays will be archived on the company's investor website for 30 days.
BioAge (Nasdaq: BIOA) priced an upsized underwritten public offering of 5,897,435 shares at $19.50 per share, producing gross proceeds of approximately $115.0 million. The offering is expected to close on or about January 23, 2026, subject to customary closing conditions. BioAge granted underwriters a 30-day option to purchase up to 884,615 additional shares. All shares are being offered by BioAge; proceeds are intended to fund research, clinical and process development and manufacturing (including BGE-102 and NLRP3 and APJ programs), working capital, capex, reduction of indebtedness and general corporate purposes.
Goldman Sachs, Piper Sandler and Citigroup are joint book-running managers; the offering is made under a Form S-3 registration that became effective November 25, 2025.
BioAge (Nasdaq: BIOA) on January 20, 2026 announced a proposed underwritten public offering of up to $75.0 million of common stock, with a 30-day underwriter option to purchase up to an additional $11.25 million. All shares will be offered by the company and the offering is subject to market and other conditions with no assurance of completion or final terms. Goldman Sachs, Piper Sandler and Citigroup are joint book‑running managers. Net proceeds, together with existing cash and marketable securities, are intended to fund research, clinical and process development including BGE-102, NLRP3 and APJ programs, working capital, capex and reduction of indebtedness. The offering will be filed on Form S-3.
BioAge (Nasdaq: BIOA) is expanding development of oral NLRP3 inhibitor BGE-102 into ophthalmology, initiating a Phase 1b/2a proof-of-concept trial in diabetic macular edema (DME) in mid-2026 with results expected mid-2027. BGE-102 showed favorable tolerability in Phase 1 and robust reductions in inflammatory biomarkers (hsCRP, IL-6, IL-1β). Preclinical data report near-complete protection from retinal vascular leakage and up to 90% microvascular preservation. The DME POC will test intraocular IL-6 percent change and include BCVA and CST endpoints.
BioAge (Nasdaq: BIOA) reported interim Phase 1 MAD cohort results for BGE-102, an oral, brain-penetrant NLRP3 inhibitor for patients with obesity and elevated inflammation. In the 120 mg once-daily cohort (n=14), BGE-102 achieved a 86% median hsCRP reduction at Day 14 and 93% of participants reached hsCRP <2 mg/L; 71% reached ≤1 mg/L. BGE-102 also produced a 44% median IL-6 reduction, 30% fibrinogen reduction, and 93% IL-1β suppression in an ex vivo assay. Safety was favorable with no dose-limiting toxicities. Company plans full Phase 1 readout and Phase 2a initiation in 1H 2026.
BioAge (Nasdaq: BIOA) reported positive interim Phase 1 data for BGE-102, a brain-penetrant oral NLRP3 inhibitor, on Dec 4, 2025. In SAD (10–120 mg) and initial MAD (60, 120 mg) cohorts, BGE-102 was well tolerated and showed dose-proportional pharmacokinetics supporting once-daily dosing.
Key results: IL-1β suppression 90–98% at Day 14 (60–120 mg), and CSF concentrations at ≥60 mg exceeded target IC90 after 14 days, indicating high brain penetration. MAD plasma levels at ≥60 mg exceeded IC90 for 24 hours.
The company expanded MAD cohorts to enroll obese participants with elevated hsCRP; data are anticipated in 1H 2026. Phase 2a is planned to start in 1H 2026 with ~100 patients and a 2H26 readout.
BioAge Labs (NASDAQ: BIOA) will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 2-4, 2025. Company leaders Kristen Fortney, PhD, CEO, and Dov Goldstein, MD, CFO, will participate in a fireside chat on December 4, 2025 from 1:30–1:55 PM ET and will hold one-on-one meetings.
A live webcast will be available with registration, and replays will be archived in the company investor section at https://ir.bioagelabs.com/ for 30 days after the presentations.
BioAge Labs (NASDAQ: BIOA) will present at the Jefferies Global Healthcare Conference in London on November 17–20, 2025. The company said CEO Kristen Fortney, PhD, and CFO Dov Goldstein, MD, will join a fireside chat on Monday, November 17 from 7:30–7:55 AM ET (12:30–1:00 PM GMT) and will hold one-on-one meetings.
Investors can watch a live webcast by registering via the company link and access replays in the investor section at https://ir.bioagelabs.com/; replays will be archived for 30 days after the presentations.